

COMPLETE LISTING OF ALL CLAIMS

1. (Withdrawn) An isolated polynucleotide molecule encoding a heavy chain variable domain of antibody B2G4, said polynucleotide molecule comprising nucleotides 1 to 378 of SEQ ID NO:8.
2. (Withdrawn) An isolated polynucleotide molecule encoding a light chain variable domain of antibody B2G4, said polynucleotide molecule comprising nucleotides 1 to 372 of SEQ ID NO:9.
3. (Withdrawn) An isolated polynucleotide molecule encoding an antibody-binding fragment, said antibody-binding fragment comprising at least one heavy chain variable domain encoded by the polynucleotide set forth in SEQ ID NO:8 and at least one light chain variable domain encoded by the polynucleotide set forth in SEQ ID NO:9.
4. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein said antibody-binding fragment is an scFV fragment.
5. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein said antibody-binding fragment is a diabody.
6. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein the antibody-binding fragment is a triabody.
7. (Currently Amended) An isolated antibody or antibody-binding fragment, wherein said isolated antibody or antibody-binding fragment comprises a heavy chain comprising the amino acid sequence encoded by nucleotides 1 to 378 of

- SEQ ID NO: 8, and wherein said isolated antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO: 4.
8. (Cancelled) The antibody or antibody-binding fragment of claim 7, wherein said heavy chain comprises an amino acid sequence encoded by nucleotides 1 to 378 of SEQ ID NO:8, and wherein said antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO:4.
 9. (Currently Amended) An isolated antibody or antibody fragment, wherein said isolated antibody or antibody-binding fragment comprises a light chain comprising the amino acid sequence encoded by nucleotides 1 to 372 of SEQ ID NO: 9, and wherein said isolated antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO: 4.
 10. (Cancelled) The antibody or antibody-binding fragment of claim 9, wherein said light chain comprises an amino acid sequence encoded by nucleotides 1 to 372 of SEQ ID NO:9, and wherein said antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO:4.
 11. (Currently Amended) An isolated antibody or antibody-binding fragment, wherein said isolated antibody or antibody-binding fragment comprises at least one heavy and at least one light chain, and wherein said heavy chain comprises the amino acid sequence encoded by nucleotides 1 to 378 of SEQ ID NO: 8, and wherein said light chain comprises the amino acid sequence encoded by nucleotides 1 to 372 of SEQ ID NO: 9, and wherein said antibody or antibody-binding fragment specifically binds to the peptide of SEQ ID NO: 4.

12. (Cancelled) The antibody or antibody-binding fragment of claim 11, wherein said heavy chain comprises an amino acid sequence encoded by nucleotides 1 to 378 of SEQ ID NO:8, and wherein said light chain comprises an amino acid sequence encoded by nucleotides 1 to 372 of SEQ ID NO:9, and wherein said antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO:4.
13. (Newly Amended) The antibody or antibody-binding fragment according to claim 7, wherein said antibody-binding fragment is an scFV fragment.
14. (Newly Amended) The antibody or antibody-binding fragment according to claim 9, wherein said antibody-binding fragment is an scFV fragment.
15. (Newly Amended) The antibody or antibody-binding fragment according to claim 11, wherein said antibody-binding fragment is an scFV fragment.
16. (Newly Amended) The antibody or antibody-binding fragment according to claim 11, wherein said antibody-binding fragment is a diabody.
17. (Newly Amended) The antibody or antibody-binding fragment according to claim 11, wherein the antibody-binding fragment is a triabody.
18. (Cancelled) A pharmaceutical composition comprising the antibody or antibody-binding fragment of claim 7, and a pharmaceutically acceptable carrier.
19. (Cancelled) A pharmaceutical composition comprising the antibody or antibody-binding fragment of claim 9, and a pharmaceutically acceptable carrier.
20. (Cancelled) A pharmaceutical composition comprising the antibody or antibody-binding fragment of claim 11, and a pharmaceutically acceptable carrier.